Lilly's Foundayo Oral Obesity Drug Reaches Nearly 6,000 Prescriptions in Third Week Post-Launch
LLY sits 51% above its 52-week low of $623.78 on elevated volume (2.5× avg).
Summary
Eli Lilly's new oral obesity drug, Foundayo, recorded 5,612 prescriptions in its third week post-launch, according to analysts citing IQVIA data. This follows 3,707 prescriptions reported in its second week, indicating continued early uptake for the drug, which was approved on April 1. This early commercial data is crucial for investors assessing Foundayo's market penetration in the highly competitive obesity treatment landscape. While initial uptake is perceived as modest compared to rival Novo Nordisk's Wegovy, Lilly executives suggest potential data capture issues, noting over 20,000 patients have been treated. Traders will closely monitor future prescription trends over the next 8-12 weeks to gain a clearer understanding of Foundayo's commercial momentum and its ability to capture market share.
At the time of this announcement, LLY was trading at $941.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $883B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.